Pronova BioPharma ASA, which has a patented method of extracting and concentrating omega-3 ethyl esters from fish oil, is having its shares listed on the Oslo Stock Exchange in an initial public offering (IPO) of 105,915,432 shares at a price of between NOK 23 and NOK 29 per share.
Omega Pharma NV is spinning out its professional health division, Arseus NV., with an Initial Public Offering (IPO) of 23.5 million shares on the Euronext in Brussels and Amsterdam.
Evotec AG has reached an agreement to acquire Renovis Inc of San Francisco, California, in an all stock transaction valued at about $151.8 million
IDEA AG, a privately held German biopharmaceutical company, has licensed its non-steroidal, anti-inflammatory drug and delivery product, Diractin, to Alpharma Ireland Ltd, an affiliate of Alpharma Inc., a US specialty pharmaceutical company.
DSM Venturing BV, the venture capital arm of Royal DSM NV of the Netherlands, has made a €2 million equity investment in Jurilab Oy, in what Jurilab’s chief executive, Kari Paukkeri, describes as a “strategic alignment.”
Germany’s Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung) has disclosed that it will make more than €400 million available for grants to the life sciences in 2008, representing an increase of €46 million or 13% from its budget for 2007.
Vivalis, a French company that has developed a stem cell technology for the manufacture of vaccines, has made an initial public offering of shares on the mid-cap section of the Euronext Paris stock exchange, worth about €46.4 million.
Silence Therapeutics Plc, which specialises in the technology of RNA-mediated interference for the treatment of disease, has begun a three-year research and development collaboration with AstraZeneca Plc valued at up to £200 million.
Zeta Biotech, which specialises in products for the separation of molecules through the use of gel electrophoresis, is raising about €1 million with an initial public offering of 206,065 shares on the Euronext’s Marché Libré in Paris.
The Wellcome Trust, Britain’s biggest medical charity, has allocated £79 million from 2007 to 2010 for seed projects that commercial investors would not ordinarily touch.